Scholar Rock Holding Corporation (SRRK) Dividend History

Scholar Rock Holding Corporation (SRRK) is a biopharmaceutical company focused on discovering and developing medicines that target growth factors involved in serious medical conditions. Its approach emphasizes precision medicine aimed at diseases such as fibrosis and cancer, utilizing its proprietary drug discovery platform to develop first-in-class therapeutics.

301 Binney Street, Cambridge, MA, 02142
Phone: 857-259-3860
Website: https://www.scholarrock.com

Dividend History

Scholar Rock Holding Corporation currently does not pay dividends

Company News

Why Scholar Rock Holding Stock Topped the Market Today

Biotech stock Scholar Rock (SRRK) jumped nearly 3% on Wednesday after a positive analyst note from Piper Sandler's Allison Bratzel. Bratzel believes the company's lead drug candidate, apitegromab, is undervalued and could see significant upside if approved for treating spinal muscular atrophy (SMA).

The Motley Fool
Wall Street Breakfast: The Week Ahead

This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.

Seeking Alpha

Featured Companies: AAPL AMD AMGN AMZN ANVS ATGL BKNG CHGG COP COTY CTNM CVS CZR DASH DD DPZ EBAY FTNT H HSY KHC KO KOPN LLY LMND LNG LXEO MA MAMO MAR MCD MDB MDLZ MED MET MGA MGM MSTR NXPI OCUL ON PAA PFE PRTS PYPL QCOM RIOT SBUX SGMT SMCI SMR TEAM TSLA
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle loss. The analysis focuses on the potential of their lead program, apitegromab, for Spinal Muscular Atrophy (SMA), which is currently in a Phase 3 trial (SAPPHIRE) with data expected in Q4 2024. Apitegromab benefits from robust Phase 2 data (TOPAZ) and shows promise as an add-on therapy to existing treatments for SMA. The analyst commences coverage of Scholar Rock with a Strong Buy rating ...Full story available on Benzinga.com

Benzinga
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research

Page data last updated 07/22/2025 19:16:14 UTC